MacroGenics Announces Additional DART Funding

One of the very famous and private bio-technology based Company is MacroGenics. The Company has its focus on the discovery and more findings for disorders which are related to autoimmune, cancer and also diseases which are come in the category of infectious. They aid to search for a solution for patients suffering from such disorders and defects which are discovered over a period of time. The Company has recently been funded with an astounding sum of $9.8 million to be used for aiding the researched and new discoveries related to “Dual-Affinity Re-Targeting (DART)”. This grant has been provided by National Institutes of Health (NIH). Not only will this fund be used to find new information on DART which may be a very major help if fully discovered.

It was found that the DART has its main target as B lymphocytes; this in turn has very good chances of throwing a light on the treatment of varied diseases like multiple sclerosis, rheumatoid arthritis, lupus and other various disorders. MacroGenics has been advancing in three specified areas, the cancer stem-like cell, which if fully developed can be a major breakthrough, the Fc optimization, this aims to advance the antibody-dependent effectors functions and the other major developmental research going on is the most talked about DART.

The researched article on DART has been published in the science journal of “Arthritis & Rheumatism” and in “Journal of Molecular Biology”. Moreover the advances made at every stage regarding DART has been offered in many science conference .NIH has funded MacroGenics to research and find more on the treatment of infectious pathogens which causes diseases like prophylaxis and Dengue Virus. If researched more the DART has immense potential to create new therapeutics which would be a drastic leap which would give health a new dimension.

Be the first to comment on "MacroGenics Announces Additional DART Funding"

Leave a comment

Your email address will not be published.